Myriad Genetics
Myriad Genetics is a genetic testing company in Salt Lake City, Utah, listed on NASDAQ as MYGN, that runs its tests in its own accredited laboratories. Most of what it sells is laboratory testing: the MyRisk hereditary cancer panel, GeneSight pharmacogenomic testing for mental health medications, Prequel prenatal screening, the Foresight carrier screen, Precise Tumor profiling, Precise MRD monitoring and the MyChoice CDx companion diagnostic. In October 2026 Myriad agreed to sell its Prenatal Health testing business, which includes Prequel and Foresight, to Labcorp, in a deal it expects to close by early 2027.
The learned models sit in two places. RiskScore, offered with MyRisk, combines a polygenic risk score with the Tyrer-Cuzick clinical model to estimate a woman's remaining lifetime risk of breast cancer, and since 2021 weights its risk variants by each woman's genetic ancestry so that it can be reported for all ancestries. Prolaris + AI, launched in May 2026, combines Myriad's Prolaris cell cycle progression score with PATHOMIQ_PRAD, a digital pathology model Myriad has licensed exclusively from PATHOMIQ since February 2025, to predict whether a prostate cancer on active surveillance will be upgraded at the next biopsy; its development and validation were published in Future Oncology in June 2026.
Capability Axes
An AI Health Index grade measures what a buyer can verify from public sources on the date shown. It is not a rating of how good the product is. A vendor can build an excellent system and grade low on an axis because it publishes nothing an outsider can check. How grades read
Artificial intelligence is a feature layer on a laboratory testing business whose value stands without it. What Myriad sells is sequencing and expression testing run in its own laboratories: hereditary cancer panels, pharmacogenomics, prenatal and carrier screening, tumor profiling and residual disease monitoring.
Two learned components sit on top. RiskScore is a polygenic risk score, a weighted sum of breast cancer risk variants with weights set by each woman's genetic ancestry, combined with the Tyrer-Cuzick clinical model to estimate lifetime breast cancer risk; it is offered with MyRisk to women whose panel finds no pathogenic variant. Prolaris + AI adds PATHOMIQ's digital pathology model to the Prolaris expression score for men on active surveillance. Both change the answer a clinician receives, and both ride on an assay that is sold and reimbursed without them.
The score reaches an ordering clinician as part of a laboratory report, and the controls around it are not described. RiskScore returns a lifetime breast cancer risk estimate that informs screening and prevention decisions, and Prolaris + AI returns a risk of upgrading that informs whether a man stays on active surveillance. In both cases a clinician receives the result and decides, which is review before action.
What is not published is the mechanism: who signs out the model derived score in the laboratory, which results the system will not report, how a score is handled when the input falls outside the validated range, and how a corrected score reaches a patient already managed on the earlier one.
The approach and the supplier are named, without version and update practice. RiskScore's construction is published: 149 ancestry informative variants to estimate ancestry, a weighted sum of 93 breast cancer risk variants with ancestry specific weights, and combination with the Tyrer-Cuzick model. Prolaris + AI is described as Myriad's cell cycle progression expression score combined with clinical and pathological features and PATHOMIQ's independent AI powered digital pathology analysis, producing a Gleason upgrade risk score.
What is not published is version discipline: which RiskScore version a report reflects, how variant weights are updated as reference data grow, and how changes to PATHOMIQ's model reach the Prolaris + AI result.
The chain is short and the outside party is named. RiskScore is built and run by Myriad on its own laboratory data, with no outside model provider. Prolaris + AI names its one outside model supplier, PATHOMIQ, whose digital pathology technology is integrated into the test.
What is not published is the terms between them: whether PATHOMIQ receives slide images or patient data, whether it retains or trains on them, and under what agreement. The privacy notice says outside service providers act as business associates without naming them, and no subprocessor list is published.
Published research on both models, short of independent validation. Myriad reports a retrospective study in Genetics in Medicine (2024) of more than 130,000 women tested with MyRisk between 2017 and 2019, linking test results to medical claims, in which RiskScore improved predictive accuracy roughly two fold over Tyrer-Cuzick alone and reclassified about one woman in five; better calibration and discrimination are reported without the figures on the release. The all ancestry version was developed on more than 189,000 women and validated on more than 89,000 (ASCO 2021 abstract).
Prolaris + AI was trained on 998 active surveillance candidates and validated on 296, all with Gleason 3+3 or 3+4 disease, and its Gleason upgrade score was a significant predictor of upgrading at the next biopsy. That work, first posted as a preprint, was published in Future Oncology in June 2026 (Mabey and colleagues). A 2026 meta analysis of 8,478 patients in Clinical Genitourinary Cancer reports that the Prolaris score predicts distant metastasis and prostate cancer specific death independently of clinical factors, with a hazard ratio of 2.28. The studies are company led and none is a prospective trial of either score.
The training position is stated broadly and in Myriad's favor, and retention is left general. The privacy notice says Myriad may use de identified data to develop and improve its genetic tests, contribute to its variant classification program and conduct research alone or with others, and that once data is de identified it may be used or disclosed for any lawful purpose. It says identifiable information is retained as part of the medical record for as long as services and legal requirements need, without a schedule for samples or sequence data, and it names no de identification method.
A grant to develop products on patient data, however clearly worded, describes what Myriad may do with the data rather than how it is protected. Safety engineering for RiskScore or Prolaris + AI, meaning guardrails and how a faulty score would be detected and handled, is not published.
Covered entity status is stated and a substantive privacy document reaches the patient. Myriad's HIPAA Notice of Privacy Practices, last updated 30 July 2026, says its testing subsidiaries are each covered entities under HIPAA, describes uses and disclosures, and says business associates inside and outside the Myriad family are bound by contract and by law to protect the information they receive. A separate privacy notice covers the website.
As a covered entity laboratory, Myriad contracts with health systems as a provider of testing rather than as their business associate, so no business associate agreement for customers is published, and the notice does not list which outside parties receive genetic data.
A recognized certification is named without the artifact. Myriad's IT security page displays a HITRUST r2 two year certification badge alongside its laboratory credentials (CLIA, CAP, ISO 15189, ISO 13485) and PCI and SOX compliance, and describes security built into its systems and third party vendor screening.
Its laboratory certificates (CAP, CLIA, ISO 13485, ISO 15189 and state licenses) can be downloaded from a certificates page, but the HITRUST letter, its date and its scope are not published, so a buyer cannot tell whether it covers the systems that compute RiskScore or receive pathology images. The laboratory standards address testing quality rather than information security, and no penetration testing statement, vulnerability disclosure program or SOC 2 report is published.
The lead products are offered as laboratory developed tests, and that position is stated. Myriad's May 2026 release describes Prolaris + AI as a laboratory developed test available in the United States outside New York, with New York approval expected; RiskScore is reported within MyRisk from Myriad's CLIA certified and CAP accredited laboratory. No FDA clearance is claimed for either model.
Myriad does hold an FDA approved companion diagnostic, MyChoice CDx, which identifies homologous recombination deficiency for treatment selection; that approval covers that assay and not the risk models, and in October 2026 Myriad announced work with SOPHiA GENETICS and AstraZeneca to extend it to prostate cancer with a genomic instability score. The models inform screening and surveillance decisions, so the laboratory developed test route is the governing position rather than a gap.
Results are compared across the groups RiskScore serves, with the weaker group visible. Polygenic scores are known to perform differently by ancestry, and Myriad's published summary of its all ancestry RiskScore (ASCO 2021, posted on Myriad's site) states the method: ancestry informative variants estimate each woman's fractional African, East Asian and European ancestry, and the weights on the breast cancer risk variants follow that composition. It then reports results by group: women in the top decile carried roughly double the average risk in each group except Black and African women, where the increase was 44 percent, and at least 95 percent of the risk variants were common enough in each self reported population to contribute.
No per group counts, discrimination or calibration figures are given in that summary, and Prolaris + AI publishes no results by race or ancestry, a gap for a test used in a disease with known racial differences in outcomes.
Myriad is the covered entity laboratory, the model derived score is part of the result it reports, and its Notice of Privacy Practices gives the patient a right to have that record amended. The notice says a patient who believes the information Myriad holds is incomplete or incorrect may request an amendment, a route the patient exercises against Myriad directly and that reaches the reported result.
No error rate is published for either model at its reporting threshold, and no warranty, indemnity or remediation commitment attaches to a RiskScore or Prolaris + AI result. Results reach a clinician who decides, which is the main protection against a wrong score.
Named record systems with two way ordering and results, without a named live site. Myriad's integrations page describes bidirectional order and results integration with Epic, where all Myriad offerings are available through the Aura network and Myriad is a founding member, and names athenahealth, eClinicalWorks, NextGen Office, Greenway, Practice Fusion and OncoEMR through Flatiron Health. Results return to the record visible across the organization, with variant level data for genomic care planning and VCF files for research.
No health system is named as live on these pages, and how RiskScore appears in the chart, as a discrete value or inside the report document, is not described.
A single service model with location implied. Myriad runs testing and scoring in its own accredited laboratories, headquartered in Salt Lake City and licensed in states including California, Maryland, New York, Pennsylvania and Rhode Island, and returns results by portal and record integration. The digital pathology step in Prolaris + AI draws on PATHOMIQ's technology, and nothing published says whether slide images are processed by Myriad or by its partner, or where.
No hosting provider, data location commitment or retention location for sequence data and slide images is published.
A pricing basis with figures is published for patients, without institutional tiers. Myriad's MyRisk cost page says most eligible patients pay nothing after insurance or financial assistance, that 95 percent of commercial and federally funded plans cover hereditary cancer testing, and that financial assistance places patients at $0, $100 or $249 by household income and size.
The virtual care route charges $39 for the test kit at order and asks patients to call if the estimate exceeds $249; interest free payment plans start at $15 a month. No separate charge for RiskScore is published. A self pay route at a fixed price is offered without the figure, and Prolaris + AI pricing is not published.
Coverage is named with validation behind the two models. RiskScore is for breast cancer risk in women tested with MyRisk, and its all ancestry version was developed and validated across African, East Asian and European continental ancestry components. Prolaris + AI is scoped to men with Gleason 3+3 or 3+4 prostate cancer who are candidates for active surveillance, matching its validation cohort, and is available in the United States outside New York pending state approval. The wider test menu covers oncology, women's health, prenatal care, urology and mental health prescribing, where the assays rather than a model carry the result.
Product updates
Material product, regulatory, evidence and commercial changes at Myriad Genetics, each verified against a live source and tagged to the capability axis it bears on. Funding rounds and awards are not product changes and are not logged.
Myriad released MONSTAR-SCREEN-3 data on Precise MRD, its whole genome sequencing test for residual cancer, presented at ESMO 2026. In resectable colorectal cancer the test found tumor DNA before clinical recurrence in every recurrence observed, with a median lead time of four months, and more than half of positive results after surgery were below 100 parts per million. In resectable pancreatic cancer, a positive result one month after surgery was linked to significantly worse recurrence free survival.
Alternatives to Myriad Genetics
Other products that do the same kind of work as Myriad Genetics, and what each one does.
Invitae is a genetic testing brand owned by Labcorp, which acquired the business in 2024 after Invitae's bankruptcy. It keeps its own site and test menu and now presents itself as Invitae and Labcorp together, with some billing handled by Labcorp Genetics.
Ambry Genetics is a genetic testing laboratory in Aliso Viejo, California, founded in 1999 and owned since 2025 by Tempus AI.
Genomics company in San Mateo, California, sequencing with its proprietary Exome+ assay in a CLIA certified, CAP accredited laboratory.
Allelica, based in San Francisco, builds polygenic risk scores and sells them several ways.
MyOme is a genomics company in Menlo Park, California, with a CLIA certified and CAP accredited laboratory, that sells whole genome screening built around integrated risk scores.
Guardant Health is a publicly traded precision oncology company (Nasdaq: GH), founded in 2012 and based in Palo Alto, California, that runs blood and tissue cancer tests in its own laboratories.
Compared With
Each comparison carries a written verdict, the buyer conditions that favor each vendor, and a graded side by side. Pairs that cross a category boundary are grouped separately, and their verdicts state where the boundary sits rather than manufacturing a head to head.
Head to head
Vendors the index assesses as direct competitors to Myriad Genetics for the same buyer.
Adjacent comparisons
Products a buyer researches alongside Myriad Genetics that do a different job: a different category, a different layer of the stack, or a specialist scope. These pages exist to settle whether the comparison is real before it settles which one to pick.
Pricing
Vendor-published figures are labeled as such. Figures labeled “Estimated” are derived from third-party sources and have not been confirmed by the vendor.
| Entry Price | Pricing Basis | BAA Tier | Implementation | Source |
|---|---|---|---|---|
|
Most eligible patients pay $0; financial assistance tiers of $0, $100 or $249
|
Laboratory tests billed to insurance, with income based patient assistance tiers, a $39 kit fee on the virtual care route and payment plans from $15 a month (MyRisk cost page). | Myriad's testing subsidiaries are HIPAA covered entities; no customer business associate agreement applies to ordered testing, and the outside parties that receive genetic data are not listed. | None published. Record integrations with Epic, athenahealth, eClinicalWorks and others are offered. | Vendor Published |
Myriad publishes patient facing figures for MyRisk: most eligible patients pay nothing after insurance or assistance, assistance tiers place patients at $0, $100 or $249 by income and household size, the virtual care route charges $39 for the kit, and payment plans start at $15 a month. A fixed self pay price is offered without the figure. RiskScore carries no separate published charge, and Prolaris + AI, GeneSight and other test prices, and any institutional rates for health system programs, are not published.